 Connection
Shi-Ming Tu to Middle Aged
This is a "connection" page, showing publications Shi-Ming Tu has written about Middle Aged.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.433 |
|
|
|
-
Chahoud J, Zhang M, Pisters LL, Lin SC, Lin SH, Tu SM. Identification of Glypican-3 (GPC3) Expression in a Lethal Subgroup of Refractory Cisplatin-Resistant Testicular Germ-Cell Tumors. Clin Genitourin Cancer. 2018 10; 16(5):325-327.
Score: 0.055
-
Bilen MA, Hess KR, Subudhi SK, Aparicio A, Kim J, Zurita-Saavedra AJ, Araujo JC, Corn PG, Stover J, Lin SH, Logothetis CJ, Tu SM. Clinical predictors of survival in patients with castration-resistant prostate cancer receiving sipuleucel-T cellular immunotherapy. Cancer Chemother Pharmacol. 2017 Sep; 80(3):583-589.
Score: 0.051
-
Bilen MA, Hess KR, Campbell MT, Wang J, Broaddus RR, Karam JA, Ward JF, Wood CG, Choi SL, Rao P, Zhang M, Naing A, General R, Cauley DH, Lin SH, Logothetis CJ, Pisters LL, Tu SM. Intratumoral heterogeneity and chemoresistance in nonseminomatous germ cell tumor of the testis. Oncotarget. 2016 Dec 27; 7(52):86280-86289.
Score: 0.049
-
Tu SM, Bilen MA, Hess KR, Broaddus RR, Kopetz S, Wei C, Pagliaro LC, Karam JA, Ward JF, Wood CG, Rao P, Tu ZH, General R, Chen AH, Nieto YL, Yeung SC, Lin SH, Logothetis CJ, Pisters LL. Intratumoral heterogeneity: Role of differentiation in a potentially lethal phenotype of testicular cancer. Cancer. 2016 06 15; 122(12):1836-43.
Score: 0.047
-
Bilen MA, Reyes A, Bhowmick D, Maa A, Bast R, Pisters LL, Lin SH, Logothetis CJ, Tu SM. Variant prostate carcinoma and elevated serum CA-125. Can J Urol. 2014 Oct; 21(5):7442-8.
Score: 0.042
-
Som A, Zhu R, Guo CC, Efstathiou E, Xiao L, Pisters LL, Matin A, Tu SM. Recurrent seminomas: clinical features and biologic implications. Urol Oncol. 2012 Jul-Aug; 30(4):494-501.
Score: 0.032
-
Tu SM, Lopez A, Leibovici D, Bilen MA, Evliyaoglu F, Aparicio A, Guo CC, Kuban DA, Johnson MM, Pisters LL. Ductal adenocarcinoma of the prostate: clinical features and implications after local therapy. Cancer. 2009 Jul 01; 115(13):2872-80.
Score: 0.029
-
Tu SM, Reyes A, Maa A, Bhowmick D, Pisters LL, Pettaway CA, Lin SH, Troncoso P, Logothetis CJ. Prostate carcinoma with testicular or penile metastases. Clinical, pathologic, and immunohistochemical features. Cancer. 2002 May 15; 94(10):2610-7.
Score: 0.018
-
Hwang MJ, Hamza A, Zhang M, Tu SM, Pisters LL, Czerniak B, Guo CC. Somatic-type Malignancies in Testicular Germ Cell Tumors: A Clinicopathologic Study of 63 Cases. Am J Surg Pathol. 2022 01 01; 46(1):11-17.
Score: 0.018
-
Ranasinghe W, Shapiro DD, Hwang H, Wang X, Reichard CA, Elsheshtawi M, Achim MF, Bathala T, Tang C, Aparicio A, Tu SM, Navone N, Thompson TC, Pisters L, Troncoso P, Davis JW, Chapin BF. Ductal Prostate Cancers Demonstrate Poor Outcomes with Conventional Therapies. Eur Urol. 2021 02; 79(2):298-306.
Score: 0.016
-
Ranasinghe WKB, Brooks NA, Elsheshtawi MA, Davis JW, Bathala TK, Tang C, Troncoso P, Aparicio A, Tu SM, Pisters LL, Chapin BF. Patterns of metastases of prostatic ductal adenocarcinoma. Cancer. 2020 08 15; 126(16):3667-3673.
Score: 0.016
-
Mathew P, Tannir N, Tu SM, Wen S, Guo CC, Marcott V, Bekele BN, Pagliaro L. Accelerated disease progression in prostate cancer and bone metastases with platelet-derived growth factor receptor inhibition: observations with tandutinib. Cancer Chemother Pharmacol. 2011 Oct; 68(4):889-96.
Score: 0.008
-
Guo CC, Punar M, Contreras AL, Tu SM, Pisters L, Tamboli P, Czerniak B. Testicular germ cell tumors with sarcomatous components: an analysis of 33 cases. Am J Surg Pathol. 2009 Aug; 33(8):1173-8.
Score: 0.007
-
Spiess PE, Tannir NM, Tu SM, Brown GA, Liu P, Kamat AM, Wood CG, Evans JG, Pisters LL. Viable germ cell tumor at postchemotherapy retroperitoneal lymph node dissection: can we predict patients at risk of disease progression? Cancer. 2007 Dec 15; 110(12):2700-8.
Score: 0.007
-
Spiess PE, Tannir NM, Brown GA, Liu P, Tu SM, Evans JG, Pisters LL. Recurrence in nonseminomatous germ cell testis tumor patients with no viable tumor at postchemotherapy retroperitoneal lymph node dissection. Urology. 2007 Dec; 70(6):1173-8.
Score: 0.007
-
Spiess PE, Kassouf W, Brown GA, Kamat AM, Liu P, Gomez JA, Tu SM, Tannir NM, Pisters LL. Surgical management of growing teratoma syndrome: the M. D. Anderson cancer center experience. J Urol. 2007 Apr; 177(4):1330-4; discussion 1334.
Score: 0.006
-
Leibovici D, Spiess PE, Agarwal PK, Tu SM, Pettaway CA, Hitzhusen K, Millikan RE, Pisters LL. Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level. Cancer. 2007 Jan 15; 109(2):198-204.
Score: 0.006
-
Spiess PE, Brown GA, Liu P, Tu SM, Tannir NM, Evans JG, Kamat AM, Kassouf W, Pisters LL. Recurrence pattern and proposed surveillance protocol following post-chemotherapy retroperitoneal lymph node dissection. J Urol. 2007 Jan; 177(1):131-8.
Score: 0.006
-
Spiess PE, Brown GA, Pisters LL, Liu P, Tu SM, Evans JG, Kamat AM, Black P, Tannir NM. Viable malignant germ cell tumor in the postchemotherapy retroperitoneal lymph node dissection specimen: can it be predicted using clinical parameters? Cancer. 2006 Oct 01; 107(7):1503-10.
Score: 0.006
-
Spiess PE, Brown GA, Liu P, Tannir NM, Tu SM, Evans JG, Czerniak B, Kamat AM, Pisters LL. Predictors of outcome in patients undergoing postchemotherapy retroperitoneal lymph node dissection for testicular cancer. Cancer. 2006 Oct 01; 107(7):1483-90.
Score: 0.006
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|